The Medicines and Healthcare products Regulatory Agency approved beremagene geperpavec, marketed as Vyjuvek, on 15 May 2026 for the treatment of wounds in patients with dystrophic epidermolysis bullosa. The authorisation applies from birth onwards and was granted to Krystal Biotech Netherlands, B.V. As a UK regulatory decision, it creates a new licensed option for a very small patient group living with a condition marked by chronic skin fragility and repeated wound formation. For a policy and regulatory audience, the immediate point is clear. This is a medicines authorisation issued by the MHRA, rather than an early access measure or a research-only development. It establishes the product's UK regulatory status for use within the terms of its licence.
As the MHRA notice explains, dystrophic epidermolysis bullosa is a rare inherited condition caused by a gene fault that prevents the layers of skin from holding together properly. The result is fragile skin, blistering and wounds that can recur or remain difficult to heal. That background matters because wound control is central to day-to-day care in this patient group. Vyjuvek is supplied as a gel and is applied directly to wounds. The MHRA says the medicine works by placing a copy of the relevant gene into cells in the wound to help the skin heal. The agency has also stated that the modified virus and genetic material used in the medicine do not alter the patient's DNA.
The efficacy evidence cited by the MHRA comes from a study involving 31 patients aged between 1 and 44 years with dystrophic epidermolysis bullosa. At six months, 67 per cent of wounds treated with beremagene geperpavec were completely healed, compared with 22 per cent of wounds treated with placebo. In regulatory terms, that is the key comparative result underpinning the announcement. The study size is modest, but that is not unusual in rare disease medicine development where patient populations are limited. In this setting, regulators tend to focus closely on whether the treatment effect is clinically meaningful and whether post-authorisation monitoring is robust enough to track safety and effectiveness in wider use.
Julian Beach, the MHRA's Executive Director of Healthcare Quality and Access, said the approval provides a new treatment option for people living with dystrophic epidermolysis bullosa. He also said the regulator would continue to monitor the safety and effectiveness of beremagene geperpavec as it is used more widely. That point is important because it frames the decision as the start of an ongoing evidence and safety process, not the end of one. The MHRA has directed clinicians and patients to the product literature for the full list of reported side effects. In practice, the Summary of Product Characteristics and the Patient Information Leaflet will be the main reference documents for prescribing, administration and risk communication once published.
The approval was submitted and granted through the International Recognition Procedure. In plain terms, that shows the MHRA using one of its recognition-based regulatory routes while still issuing the final UK authorisation decision itself. For sponsors, the route matters because it shapes the submission pathway. For clinicians and families, the more immediate issue is that the medicine now has a defined UK regulatory basis. According to the government notice, the Summary of Product Characteristics and Patient Information Leaflet will be published on the MHRA products website within seven days of approval. Those documents will set out the authorised indication, method of use and the adverse reactions reported to date.
The decision is notable for three practical reasons set out in the announcement. It concerns a rare inherited condition with substantial care needs, it applies from birth onwards, and it authorises a treatment that is applied directly to the wound. That combination makes the approval relevant not only to specialist dermatology and rare disease teams, but also to those tracking how the UK system is handling advanced and highly targeted therapies. The announcement does not answer every downstream access question, but it does settle the core regulatory issue. For families affected by dystrophic epidermolysis bullosa, the immediate significance is that a new licensed treatment option now exists in the UK. For the wider policy community, the case is a clear example of the MHRA using the International Recognition Procedure to bring a novel medicine through to authorisation.